Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$9.16 - $25.52 $2,857 - $7,962
-312 Reduced 0.85%
36,455 $930,000
Q4 2023

Feb 13, 2024

BUY
$4.87 - $9.37 $7,241 - $13,933
1,487 Added 4.21%
36,767 $332,000
Q3 2023

Nov 13, 2023

BUY
$6.3 - $11.35 $7,900 - $14,232
1,254 Added 3.69%
35,280 $225,000
Q2 2023

Aug 04, 2023

BUY
$10.62 - $17.34 $26,762 - $43,696
2,520 Added 8.0%
34,026 $377,000
Q1 2023

May 12, 2023

BUY
$15.35 - $25.65 $95,108 - $158,927
6,196 Added 24.48%
31,506 $483,000
Q4 2022

Feb 10, 2023

BUY
$10.06 - $22.66 $10,029 - $22,592
997 Added 4.1%
25,310 $561,000
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $22,107 - $33,504
1,430 Added 6.25%
24,313 $397,000
Q2 2022

Aug 12, 2022

BUY
$11.18 - $20.5 $46,799 - $85,813
4,186 Added 22.39%
22,883 $332,000
Q1 2022

May 13, 2022

SELL
$14.2 - $23.78 $18,687 - $31,294
-1,316 Reduced 6.58%
18,697 $345,000
Q4 2021

Feb 11, 2022

SELL
$20.4 - $28.66 $12,219 - $17,167
-599 Reduced 2.91%
20,013 $476,000
Q3 2021

Nov 12, 2021

BUY
$18.16 - $25.21 $66,320 - $92,066
3,652 Added 21.53%
20,612 $508,000
Q2 2021

Aug 13, 2021

SELL
$19.62 - $29.26 $15,872 - $23,671
-809 Reduced 4.55%
16,960 $419,000
Q1 2021

May 07, 2021

BUY
$20.28 - $28.15 $163,193 - $226,523
8,047 Added 82.77%
17,769 $388,000
Q4 2020

Feb 12, 2021

SELL
$24.73 - $35.12 $6,899 - $9,798
-279 Reduced 2.79%
9,722 $248,000
Q3 2020

Nov 04, 2020

BUY
$23.35 - $35.94 $233,523 - $359,435
10,001 New
10,001 $282,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.21B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.